



Department of Obstetrics and Gynaecology
Queen Mary Hospital
The University of Hong Kong



Gynaecological Oncology

Annual Report 2023



Gynaecological Oncology

Department of Obstetrics and Gynaecology

Queen Mary Hospital

The University of Hong Kong

Annual Report 2023



**HKU
Med**

**School of Clinical Medicine
Department of Obstetrics
& Gynaecology
香港大學婦產科學系**

Message from Division Head

The gynaecological oncology division of the Department of Obstetrics and Gynaecology, the University of Hong Kong, has been providing training and service in gynaecological oncology for over 50 years. Our unit is a tertiary referral center for both the private and public sectors in Hong Kong. We also accept referrals from the hospitals in Macau. With collaboration with other departments, our scope of services includes colposcopy, chemotherapy, radiotherapy, surgery and palliative care.

Our unit is a recognized training center for gynaecological oncology by the Hong Kong College of Obstetricians and Gynaecologists (HKCOG). Starting from January 2022, we had joint training programme with United Christian hospital. Dr Chiu Wan Kam from United Christian Hospital continued her second-year subspecialist training in United Christian Hospital. Dr Luk Hiu Mei started her first-year subspecialist training in Queen Mary Hospital. We had Dr Liu Bei with us for her last 6 months of joint The University of Hong Kong-Shenzhen Hospital (HKU-SZH) Gynaecological Oncological Subspecialty training programme. Starting from July 2023, we had joint training programme with Pamela Youde Nethersole Eastern Hospital. Dr Winnie Hui from Pamela Youde Nethersole Eastern Hospital started her subspecialist training in Pamela Youde Nethersole Eastern Hospital. Apart from training subspecialist fellow, we also provide gynaecological oncology training for basic and higher specialist trainees in Obstetrics and Gynaecology, not only from our unit but also other hospitals in Hong Kong.

In addition to clinical service and research activities, our division was also active in promoting women's health in Hong Kong by giving public talks and presentations in the Family Planning Association, radio and TV programmes.

I would like to take this opportunity to thank our team members and our collaborators for their contribution.



Karen K. L. Chan

Department Chairperson

Table of contents

I	Staff List	4
II	Laboratory	7
III	Inpatient & Outpatient Services	9
IV	Team Activities	10
V	Outpatient Statistics	11
VI	Colposcopy Services	12
VII	Cervical Malignancies	14
VIII	Uterine Malignancies	15
IX	Ovarian Malignancies	17
X	Gestational Trophoblastic Neoplasia	19
XI	Vulval, Vaginal and Fallopian Tube Cancers	20
XII	Multiple Primary Malignancies	21
XIII	Operations for Malignant/Pre-malignant Diseases	22
XIV	Chemotherapy	25
XV	Publications and Abstracts	27

Staff List

Gynaecological Oncologists

Professor Ngan Yuen Sheung Hextan, Professor, Department of Obstetrics and Gynaecology, School of Clinical Medicine, The University of Hong Kong

Dr. Chan Kar Loen Karen, Associate Professor, Department of Obstetrics and Gynaecology, School of Clinical Medicine, The University of Hong Kong

Dr. Tse Ka Yu, Associate Professor, Department of Obstetrics and Gynaecology, School of Clinical Medicine, The University of Hong Kong

Dr. Chu Man Yee Mandy, Consultant, Department of Obstetrics and Gynaecology, Queen Mary Hospital

Dr. Ngu Siew Fei, Associate Professor, Department of Obstetrics and Gynaecology, School of Clinical Medicine, The University of Hong Kong

Subspecialist Trainee

Dr. Kwok Shuk Tak, Associate Consultant, Department of Obstetrics and Gynaecology, Queen Mary Hospital

Dr. Luk Hiu Mei, Associate Consultant, Department of Obstetrics and Gynaecology, Queen Mary Hospital (from 1 Jan 2023)

Dr. Chiu Wan Kam, Associate Consultant, Department of Obstetrics and Gynaecology, United Christian Hospital

Dr. Winnie Hui, Associate Consultant, Department of Obstetrics and Gynaecology, Pamela Youde Nethersole Eastern Hospital (from 1 Jul, 2023)

Dr. Liu Bei, Resident Specialist, Department of Obstetrics and Gynaecology, HKU-SZH (1 Aug 2023 – 31 Jan 2024)

Residents

Dr. Joan Wai, Resident trainee, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Jan 2023 – 31 Mar 2023)

Dr. Ma, Ka Wai, Kitty, Resident trainee, Department of Obstetrics and Gynaecology, Queen Mary Hospital (15 Feb 2023 – 31 Mar 2023)

Dr. Lam, Tsz Ching, Christy, Resident trainee, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Apr 2023 – 15 May 2023)

Dr. Chan Hey Yin, Aaron, Resident trainee, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Jul 2023 – 31 Dec 2023)

Clinical Oncologists

Dr. Yuen Kwok Keung, Chief of Service, Department of Clinical Oncology, Queen Mary Hospital

Dr. Siu Wai Kwan Steven, Consultant, Department of Clinical Oncology, Queen Mary Hospital

Pathologists

Professor Leung Suet-yi, Department Chairperson, Department of Pathology, School of Clinical Medicine, University of Hong Kong

Professor Cheung Nga Yin Annie, Professor, Department of Pathology, School of Clinical Medicine, University of Hong Kong

Prof. Ip Pun Ching Philip, Professor, Department of Pathology, School of Clinical Medicine, Queen Mary Hospital

Consultant Colorectal Surgeon

Professor Foo Chi Chung, Dominic, Clinical Associate Professor, Department of Surgery, Queen Mary Hospital

Consultant Urologist

Dr. Ng Tsui Lin, Ada, Consultant & Division Chief, Department of Surgery, Queen Mary Hospital

Consultant Plastic Surgeon

Dr. Chow Ling Yu Velda, Consultant & Division Chief, Department of Surgery, Queen Mary Hospital

Consultant Medical Oncologist

Professor Kwong Yok Lam, Division of Haematology, Medical Oncology and Bone Marrow Transplantation, Department of Medicine, School of Clinical Medicine, The University of Hong Kong

Consultant Radiologist

Dr. Cheung Chi Wai Stephen, Chief of Service, Department of Radiology, Queen Mary Hospital

Dr. Lee Yuen Phin Elaine, Clinical Associate Professor, Department of Radiology, School of Clinical Medicine, University of Hong Kong

Consultant Anaesthesiologist

Dr. Frances Lui, Chief of Service, Department of Anaesthesiology, Queen Mary Hospital

Consultant Clinical Psychologist

Dr. Lina Wu, Senior Clinical Psychologist, Department of Psychiatry, Queen Mary Hospital

Medical Social Workers

Mr Pang Kin Keung, Peter, Social Welfare Department

Nurse Specialist in Stoma Care

Ms. Chan Lai Hung, Nursing Officer, Queen Mary Hospital

Oncology Case manager:

Ms. Wong Yan Yan, Priscilla, Advanced Practice Nurse, Queen Mary Hospital

Cluster Rehabilitative Palliative Care Team

Dr. Chan Kwok Ying, Consultant, Palliative Medicine Unit, Grantham Hospital

Dr. Au Ho Yan, Toni, Associate Consultant, Palliative Medicine Unit, Grantham Hospital

Ms. Chan Wan Hung, Associate nurse consultant, Grantham Hospital

Clinical Research Team

Ms Lau Suk Kwan Lesley, Research Co-ordinator

Ms. Tang Wai Kin Iris, Research Assistant

Ms. Zhong Xiao Yan, Research Assistant

Laboratory

Staff

Dr. Chan Wai Sun, Post-doctoral Fellow
Dr. Yung Ming Ho Mingo, Post-doctoral Fellow
Dr. Liu Si Stephanie, Research Officer
Dr. Siu Kwan Yee Michelle, Research Officer
Mr. Kwok Ka Leung, Senior Technical Officer
Miss Hui Man Ning Lynn, Research Assistant
Miss Lu qiuji Jill, Research Assistant

Services

Hormonal assay and assays for tumour markers

Research tools

HPV detection and genotyping	
ELISA	Cell line and culture
Immunohistochemistry	Transfection study
In situ hybridization assay	RNAi study
DNA, RNA and protein extractions	CRISPR/Cas9 Gene Editing Clonogenic assay
Conventional PCR and RT-PCR	Cytotoxicity assay
Quantitative PCR	Cell proliferation assay
Quantitative RT-PCR	DNA copy number variation analysis
RNA protection assay	Protein co-immunoprecipitation
Western blot	Gene cloning
DNA methylation analysis	In vivo animal study
DNA sequencing	Laser-captured microdissection
Microarray analysis	3D organoids assay
Hypoxia chamber	Omics analysis
Flow cytometry	Omental conditioned medium model
Yeast two hybrid	Ex vivo omental-tumor model
Fluorescent microscopy	
Fluorescent stereomicroscopy	
Li-Cor Odyssey CLx near-infrared fluorescence imaging system	
Gel documentation system	
Microplate reader	
SpectraMax L Microplate Reader	

Inpatient Services

Gynaecological oncology ward

22 beds in the open ward

2 private beds

3 day beds

Ward Manager

Ms. Ho, Pui Yee, Polly (Ward Manager)

Operating Theatre

2 Full-day lists per week

Operating Theatre Manager

Ms. Sylvia Wong

Outpatient Services

Colposcopy Clinic	4 sessions per week
Chemotherapy Clinic	1 session per week
Cancer follow-up Clinic	1 session per week
Trophoblastic Clinic	1 session per week
Day Chemotherapy	5 days per week
Patient Group Meeting	withheld due to COVID
Palliative Medicine Clinic	1 session per week
Pre-admission Clinic	1 session per week

Clinic In-charge

Ms. Shiu, Wing Yin, Advanced Practice Nurse, S5, Queen Mary Hospital

Team Activities

Grand Round (Led by Dr. Karen Chan)	1 per week
Discussion of New Cases and Treatment (Led by Dr. Karen Chan)	1 per week
Radiology Meeting (Led by Dr. Karen Chan and Dr. Elaine Lee)	1 per week
Chemotherapy Meeting (Led by Dr. Karen Chan)	1 per week
Morbidities and Mortality Meeting (Led by Dr. Karen Chan)	1 per week
Pre-operative Round (Led by Dr. Karen Chan)	1 per week
Tumour Board Meeting/Pathology Review (Led by Dr. Karen Chan and Prof. Annie Cheung)	1 per week
Laboratory Research Meeting (Led by Dr. Karen Chan)	1 per month
Clinical Research Meeting (Led by Dr. Karen Chan)	1 per 8 weeks

Outpatient Statistics

Oncology Clinics Attendances

	2019	2020	2021	2022	2023
Cancer Follow-up Clinic	4207	3918	3318	3447	3218
Trophoblastic Clinic	667	531	573	401	372
Chemotherapy Clinic	2219	2633	2577	2690	2652
Preadmission Clinic	174	162	139	124	113
Research Clinic	15	0	0	0	0

Patient Group Meeting

Oncology patients support group which was led by:

Ms. Ho, Pui Yee, Polly (Ward Manager)
Ms. Tang Lai Chun (Advanced Practice Nurse)
Ms. Cheng Sze Ki (Registered Nurse)

Stoma patients support group which was led by:

Ms. Chan Lai Hung (Nursing Officer)

Oncology patient support group:

Withheld due to COVID & manpower shortage

Stoma patient support group:

Withheld due to COVID & manpower shortage

Annual patient group party:

Withheld due to COVID & manpower shortage

Colposcopy Services

Colposcopy Clinics

Queen Mary Hospital

4 sessions - Monday afternoon, Tuesday morning, Thursday and Friday afternoon

Cervical Smear Clinics (run by nurses)

Queen Mary Hospital

2 sessions - Monday afternoon and Tuesday morning

Statistics

New Cases	518
Follow-up	1267

Diagnosis (based on worst histology)	Cervix	Vagina	Vulva
Normal	52	17	
Inflammation	15	1	
Warts/HPV	67	8	
Low grade squamous intraepithelial lesion	181	19	
High grade squamous intraepithelial lesion	96	13	2
Microinvasive carcinoma	0		
Squamous cell carcinoma	3	1	
Adenocarcinoma	2		
Adenocarcinoma in-situ	3		
No histology	82	14	
Unsatisfactory for assessment	19	2	
Others			
Atrophy	0		
Atypical cells	3		
Endocervical polyp	1		
Metastatic adenocarcinoma	1		


Procedures

Cone biopsy	5
Cryotherapy	1

Large loop excision of transformation zone	110
Under local anaesthesia	99
Under general / spinal anaesthesia	11


Cervical Malignancies

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Total Number of New cases	84	82	87	101	73	84	91	63	77	46	69
Stage I	42	42	43	36	36	33	27	21	25	12	17
Stage II	21	19	17	26	18	24	23	10	15	13	20
Stage III	16	14	12	14	11	11	18	17	21	10	22
Stage IV	3	2	6	8	3	9	14	8	5	4	10
Unstaged	1	3	0	5	2	4	1	0	2	1	0
Recurrence	1	2	9	12	3	3	8	7	9	6	0



2023 New Case


Age	
≤ 30	1
31-40	12
41-50	17
51-60	19
61-70	15
71-80	4
> 80	1
Total	69



Uterine Malignancies


Carcinoma of Endometrium

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Total Number of New Cases	121	146	115	134	128	147	162	149	155	117	133
Stage I	70	83	69	88	81	88	106	85	97	61	67
Stage II	8	16	10	10	11	14	9	8	6	5	20
Stage III	25	26	18	23	24	26	24	18	28	26	21
Stage IV	5	12	7	9	6	13	12	23	14	12	13
Unstaged	10	8	7	2	3	5	2	7	4	11	8
Recurrence	3	1	4	2	3	1	9	8	6	2	4



2023 New Case

Age	
≤ 30	2
31-40	8
41-50	21
51-60	50
61-70	35
71-80	16
> 80	1
Total	133




Other Uterine Malignancies

	2018	2019	2020	2021	2022	2023
Endometrial stromal sarcoma	8	3	4	6	3	2
Leiomyosarcoma	7	9	5	3	5	3
Malignant mixed mullerian tumor (MMMT)	8	8	8	11	22	6
Adenosarcoma	0	0	0	0	2	1
Chondrosarcoma	0	0	0	0	0	0
Rhabdomyosarcoma	0	0	0	0	0	0
Smooth muscle tumour of undetermined malignant potential (STUMP)	1	3	2	1	3	5
Dedifferentiated endometrial carcinoma	0	0	0	0	0	0
Undifferentiated endometrial sarcoma	0	1	0	0	0	0
Uterine tumour resembling ovarian sex cord tumour	0	0	0	1	0	0
Uterine small cell carcinoma	1	0	0	0	0	0
Undifferentiated carcinoma	4	0	0	1	0	0
Sarcoma			2	2	0	4
Carcinomsarcoma			1	0	0	0
neuroendocrine				1	0	0
Carcinosarcoma with heterologous rhabdomyosarcoma					1	0
Carcinoma					1	0
malignant uterine solitary fibrous tumour						1
unusal mesenchymal tumour						1

Ovarian Malignancies


Epithelial Ovarian Cancer

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Total Number of New cases	64	78	76	76	66	79	95	51	83	63	61
Stage I	30	25	22	32	14	27	40	23	25	26	22
Stage II	7	7	5	4	11	2	8	3	5	5	5
Stage III	16	32	33	16	22	14	25	12	23	18	11
Stage IV	10	9	10	13	12	14	15	8	13	7	6
Unstaged	1	1	1	2	1	1	0	0	0	0	0
Recurrence	0	4	5	9	6	21	7	5	17	7	17



2023 New Case

Age	
≤ 30	1
31-40	5
41-50	7
51-60	23
61-70	17
71-80	7
> 80	1
Total	61



Ovarian Tumour of Low Malignant Potential

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Number of new cases	19	19	18	13	22	12	13	22	21	14	10
Stage I	14	15	16	6	19	10	12	20	17	12	5
Stage II	2	1	0	1	2	0	0	0	1	0	1
Stage III	2	2	2	1	0	1	1	1	1	1	0
Unstaged	1	0	0	0	0	0	0	1	0	1	2
Recurrence	0	1	0	4	1	0	0	0	2	0	2

Germ Cell Tumour

1 patient had stage 1a yolk sac tumour.

1 patient had recurrent yolk cell tumour.

Sex Cord-Stromal Tumour

2 patients had stage 1c1 granulosa cell tumour.

1 patient had stage 1a stertoli-Leydig cell tumour of intermediate grade of right ovary.

Other Ovarian Malignancies

1 patient had stage 2b right ovarian carcinoid neuroendocrine tumour.

1 patient likely had stage 3 or 4 high grade sarcoma or sarcomatoid carcinoma.

1 patient had at least stage 2b carcinosarcoma.


1 patient had recurrent angiomfibroblastoma.

Primary Peritoneal Carcinoma

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Total	10	10	9	15	9	11	16	10	9	6	14
Stage I	0	0	0	0	0	0	0	0	0	1	1
Stage II	0	0	0	1	0	0	0	1	0	1	0
Stage III	7	4	7	9	1	6	8	4	2	4	7
Stage IV	3	4	1	4	3	4	7	4	5	1	4
Unstaged	0	1	0	1	4	1	1	1	0	0	0
Recurrence	0	1	1	0	1	0	0	0	2	0	2


Gestational Trophoblastic Neoplasia

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Number of New cases	16	17	14	12	10	12	10	10	11	12	9
Stage I	12	10	8	8	8	9	6	8	10	11	8
Stage II	0	1	0	0	0	1	0	0	0	0	0
Stage III	2	5	2	2	2	2	2	2	1	1	1
Stage IV	2	0	1	1	0	0	1	0	0	0	0
Unstaged	0	0	0	0	0	0	1	0	0	0	0
Recurrence	0	1	1	1	0	0	0	0	0	0	0



2023 New case

Age	
≤ 30	2
31-40	2
41-50	3
> 50	2
Total	9



Vulval, Vaginal and Fallopian Tube Cancers

Vulval Cancer

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Number of New Cases	7	9	6	6	9	12	1	13	4	6	5
Stage I	4	4	0	3	6	2	0	3	0	3	1
Stage II	0	0	1	0	0	4	0	0	0	0	1
Stage III	1	3	1	1	3	1	0	4	2	2	1
Stage IV	1	0	1	0	0	1	1	2	1	1	1
Unstaged	0	1	1	1	0	2	0	3	1	0	1
Recurrence	1	1	2	1	0	2	0	1	0	0	0

Vaginal Cancer

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Number of New Cases	3	3	5	7	5	5	4	6	10	4	4
Stage I	0	1	0	0	0	0	0	0	4	2	1
Stage II	1	1	4	5	1	3	2	3	4	0	1
Stage III	0	0	0	0	1	2	0	0	1	1	0
Stage IV	2	0	1	1	2	0	0	3	0	1	1
Unstaged	0	0	0	0	0	0	1	0	0	0	0
Recurrence	0	1	0	1	1	0	1	0	1	0	1

Fallopian Tube Cancer

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Number of New Cases	0	3	2	5	4	2	1	7	5	7	9
Stage I	0	0	0	0	1	0	0	1	0	1	0
Stage II	0	0	0	1	2	0	0	1	1	0	0
Stage III	0	1	0	2	0	1	1	2	4	6	4
Stage IV	0	2	2	1	1	0	0	2	0	0	5
Unstaged	0	0	0	0	0	0	0	0	0	0	0
Recurrence	0	0	0	1	0	1	0	1	0	0	0

Multiple Primary Malignancies

		Number	
2022		14	
Primary	Stage	Primary	Stage Number
Ca Corpus	1 +	Ca Ovary	1 3
Ca Corpus	1 +	Ca Ovary	2 1
Ca Corpus	1 +	Ca Ovary	3 1
	1 +	Borderline Ovary	1 2
Ca Corpus	3 +	Ca Colon	T4aN1b 1
Ca Corpus	Unstaged +	Ca Fallopian Tube	4 1
		Borderline Ovary	1 1
Ca Ovary	1 +	Borderline Ovary	2 1
Ca Ovary	3 +		
Ca Fallopian Tube	3 +	Ca Caecum	1 1

1 patients had Ca Corpus stage 1, Ca Ovary (left) stage 1 and Borderline Ovary (right) stage 1.

1 patients had Ca Corpus stage 1 and bilateral Ca Ovary stage 1.

Operation for Malignant/Pre-malignant Diseases

	Number of procedures
Laparotomy (all cases with open abdominal surgery)	104
Radical hysterectomy +/- unilateral / bilateral salpingo-oophorectomy (U/BSO)	5
Laparoscopic radical hysterectomy +/- U/BSO	0
Laparoscopic radical hysterectomy +/- U/BSO (Da Vinci)	5
Modified radical hysterectomy +/- U/BSO	3
Laparoscopic modified radical hysterectomy +/- U/BSO (Da Vinci)	3
Total abdominal hysterectomy +/- U/BSO	79
Total laparoscopic hysterectomy +/- U/BSO	32
Total laparoscopic hysterectomy +/- U/BSO (Da Vinci)	32
VNOTES	4
Radical trachelectomy	0
Laparoscopic radical trachelectomy	0
Laparoscopic radical trachelectomy (Da Vinci)	1
Pelvic lymphadenectomy (one side)	2
Pelvic lymphadenectomy (both side)	41
Laparoscopic pelvic lymphadenectomy (one side)	0
Laparoscopic pelvic lymphadenectomy (both side)	5
Laparoscopic pelvic lymphadenectomy (one side) (Da Vinci)	1
Laparoscopic pelvic lymphadenectomy (both side) (Da Vinci)	23
Paraaortic lymphadenectomy	29
Laparoscopic paraaortic lymphadenectomy	0
Laparoscopic paraaortic lymphadenectomy (Da Vinci)	17
Omentectomy	42
Laparoscopic omentectomy	3

Laparoscopic omentectomy (Da Vinci)	2
Adhesiolysis	18
Laparoscopic adhesiolysis	1
Laparoscopic adhesiolysis (Da Vinci)	6
BSO / USO / ovarian cystectomy	6
Laparoscopic BSO / USO / ovarian cystectomy	4
Laparoscopic BSO / USO / ovarian cystectomy (Da Vinci)	15
Appendicectomy	2
Laparoscopic appendicectomy	0
Laparoscopic appendicectomy (Da Vinci)	1
Debulking surgery	24
HIPEC	4
Bowel resection and re-anastomosis	1
Colostomy / ileostomy	0
Closure of stoma	1
Repair of bowel	1
Repair of bladder	1
Repair of vessels	1
Repair of vagina / perineum	5
Vault stripping / vaginectomy	7 / 2
Wide local excision of vulva	4
Radical vulvectomy	2
Groin node dissection (one side)	4 (2)
Cone biopsy	0
Large loop excision of transformation zone	3
Brachytherapy	17
Diagnostic hysteroscopy	19
Hysteroscopic polypectomy	1

Suction evacuation	0
Laparoscopic biopsy	6
Diagnostic laparoscopy	12
Examination under anaesthesia	8
Cystoscopy	3
Staging laparotomy	19
Biopsy of sentinel LN (Da Vinci)	10
Local skin flap	1
Diaphragm stripping	1

Chemotherapy

Total number of patients receiving in-patient chemotherapy: 217

Total number of patients receiving out-patient chemotherapy: 287

Total number of patients receiving oral chemotherapy: 19

Total number of patients receiving PARP inhibitors: 62

Chemotherapy Regimen	Number of courses	
	In patient	Outpatient
Actinomycin D	2	6
Adriamycin	4	34
Adriamycin/Cisplatin	2	1
Avelumab	0	10
BEP (bleomycin, etoposide, cisplatin)	4	5
Bevacizumab	14	76
Carboplatin	1	0
Carboplatin/Etoposide	4	8
Carboplatin/Gemcitabine	6	36
Carboplatin/Gemcitabine/Bevacizumab	5	13
Carboplatin/Liposomal doxorubicin	3	16
Carboplatin/Paclitaxel	331	578
Carboplatin/Paclitaxel/Bevacizumab	14	23
Carboplatin/Paclitaxel/Bevacizumab/Pembrolizumab	5	0
Carboplatin/Paclitaxel/Dostarlumab	4	5
Carboplatin/Paclitaxel/Pembrolizumab	3	3
Cisplatin	6	66
Cisplatin/Etoposide	2	0
Cisplatin/Gemcitabine	6	10
Cisplatin/Gemcitabine/Bevacizumab	7	7
Cisplatin/Liposomal doxorubicin	2	9
Cisplatin/Paclitaxel	16	3
Cyclophosphamide (oral)	0	0
Durvalumab/Placebo+Olaparib/Placebo (study)	0	13
EMA-CO (etoposide, methotrexate and actinomycin D/ cyclophosphamide and vincristine)	21	1
Etoposide	0	15
Gemcitabine	8	30
Gemcitabine/Taxotere	2	8
Ifosfamide	12	0

Liposomal doxorubicin	5	45
Liposomal doxorubicin/Bevacizumab	0	33
Melphalan	0	21
Methotrexate (intravenous)	8	0
Niraparib	0	309
Nivolumab	1	4
Olaparib	0	271
Paclitaxel	5	29
Paclitaxel/Ifosphamide/Cisplatin	4	0
Pembrolizumab	3	45
Pembrolizumab/Lenvatinib	15	40
Taxotere	0	6
Topotecan	22	61
Topotecan/Paclitaxel/Bevacizumab	5	7
Trametinib	0	8
Total number of courses of chemotherapy	552	1855

Publication

Choi, Horace; Leung, Kathy; Chan, Karen; Bai, Yuan; Jit, Mark; Wu, Joseph. Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis. *BMC Med* 21, 48 (2023). <https://doi.org/10.1186/s12916-023-02748-3>

Nagao S, Fujiwara K, Yamamoto K, Tanabe H, Okamoto A, Takehara K, Saito M, Fujiwara H, Tan DSP, Yamaguchi S, Adachi S, Kikuchi A, Hirasawa T, Yokoi T, Nagai T, Sato T, Kamiura S, Fujishita A, Loong WW, Chan K, Syks P, Olawaye A, Ryu SY, Shigeta H, Kondo E, Yokoyama Y, Matsumoto T, Hasegawa K, Enomoto T. Intraperitoneal Carboplatin for Ovarian Cancer - A Phase 2/3 Trial. *NEJM Evid*. 2023 May;2(5):EVIDoa2200225. doi: 10.1056/EVIDoa2200225. Epub 2023 Apr 21. PMID: 38320049.

Deng T, Liu K, Chen L, Chen X, Li HW, Guo H, Zhang H, Xiang L, Feng X, Wang X, Ngan HY, Zhao J, Zou D, Liu Q, Liu J. A prospective randomized multicenter trial for lymphadenectomy in early-stage ovarian cancer: LOVE study. *J Gynecol Oncol*. 2023 May;34(3):e52. doi: 10.3802/jgo.2023.34.e52. Epub 2023 Apr 10. PMID: 37116952; PMCID: PMC10157337.

Chan WS, Mo X, Ip PPC, Tse KY. Patient-derived organoid culture in epithelial ovarian cancers-Techniques, applications, and future perspectives. *Cancer Med*. 2023 Oct;12(19):19714-19731. doi: 10.1002/cam4.6521. Epub 2023 Sep 30. PMID: 37776168; PMCID: PMC10587945.

Cheung VYT, Tang YM, Chan KKL. Medical students' perception of the application of a virtual reality training model to acquire vaginal examination skills. *Int J Gynaecol Obstet*. 2023 Jun;161(3):827-832. doi: 10.1002/ijgo.14670. Epub 2023 Jan 31. PMID: 36637241.

Kwok ST, Chan KKL, Tse KY, Chu MMY, Lau LSK, Ngan HYS, Ngu SF. Outcome after loop electrosurgical excision procedure for cervical high-grade squamous intraepithelial lesion. *Taiwan J Obstet Gynecol*. 2023 Jan;62(1):45-49. doi: 10.1016/j.tjog.2022.10.004. PMID: 36720549.

Leung SMK, Wu J, Chan KKL, Jit M. Maximising the cost-effectiveness of human

papillomavirus testing for cervical screening in the context of routine HPV vaccination in Hong Kong: abridged secondary publication. *Hong Kong Med J*. 2023 Aug;29 Suppl 4(4):11-15. PMID: 37690800.

Felix Wong, Bee Luan Khoo, Karen Kar Loen Chan. Can Liquid Biopsy Cancer Research Offering Personalized Cancer Treatment in Gynecology be a Realistic Expectation?. *Clin. Exp. Obstet. Gynecol*. 2023, 50(6), 132.
<https://doi.org/10.31083/j.ceog5006132>

Chen M, Lu H, Copley SJ, Han Y, Logan A, Viola P, Cortellini A, Pinato DJ, Power D, Aboagye EO. A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC. *J Thorac Oncol*. 2023 Jun;18(6):718-730. doi: 10.1016/j.jtho.2023.01.089. Epub 2023 Feb 10. PMID: 36773776.

Lu H, George J, Eslam M, Villanueva A, Bolondi L, Reeves HL, McCain M, Chambers E, Ward C, Sartika D, Sands C, Maslen L, Lewis MR, Ramaswami R, Sharma R. Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease. *Liver Cancer*. 2022 Jul 8;12(1):19-31. doi: 10.1159/000525911. PMID: 36872928; PMCID: PMC9982340.

Lam WWT, Ng DWL, Fielding R, Sin V, Tsang C, Chan WWL, Foo CC, Kwong A, Chan KKL. Implementing a nurse-led screening clinic for symptom distress with community-based referral for cancer survivors: A feasibility study. *Psychooncology*. 2024 Jan;33(1):e6261. doi: 10.1002/pon.6261. Epub 2023 Dec 4. PMID: 38047720.

Chan AHY, Ngu SF, Lau LSK, Tsun OKL, Ngan HYS, Cheung ANY, Chan KKL. Evaluation of an Isothermal Amplification HPV Assay on Self-Collected Vaginal Samples as Compared to Clinician-Collected Cervical Samples. *Diagnostics (Basel)*. 2023 Oct 24;13(21):3297. doi: 10.3390/diagnostics13213297. PMID: 37958193; PMCID: PMC10647996.

Oncology Committee, Asia and Oceania Federation of Obstetrics and Gynecology; Tse KY, Ushijima K, Tan AL, Intasorn P, Pariyar J, Chang CL, Domingo EJ, Konar H, Kumarasamy S, Tjokroprawiro BA, Wilailak S. A questionnaire study on disparity of cervical cancer prevention programs in Asia-Oceania. *J Obstet Gynaecol Res*. 2023 Apr;49(4):1230-1243. doi: 10.1111/jog.15566. Epub 2023 Feb 1. PMID: 36726190.

Lam EWH, Ngan HYS, Kun KY, Li DFH, Wan WY, Chan PKS. Awareness, perceptions, and acceptance of human papillomavirus vaccination among parents in Hong Kong. *Hong Kong Med J*. 2023 Aug;29(4):287-294. doi: 10.12809/hkmj2210470. Epub 2023 Jul 6. PMID: 37409372.

Leung TW, Damodaran P, Torres R, Chuncharunee S, Chu MY, Gamilla Z, Lim NR, Luna J, Huang JP, Li WH, Tran TN, Sathar J, Jaisamrarn U. Expert consensus on improving iron deficiency anemia management in obstetrics and gynecology in Asia. *Int J Gynaecol Obstet*. 2023 Nov;163(2):495-509. doi: 10.1002/ijgo.14804. Epub 2023 Apr 24. PMID: 37096333.

Chu MM, Cheung CS, Ngu SF, Tse KY, Ip PP, Cheung AN, Ngan HY, Chan KK. The Value of Four-Quadrant Cervical Biopsy in Women with Different Colposcopic Impressions. *Diagnostics (Basel)*. 2023 Jul 16;13(14):2384. doi: 10.3390/diagnostics13142384. PMID: 37510128; PMCID: PMC10378482.

Chan J, Ng DWL, Liao Q, Fielding R, Soong I, Chan KKL, Lee C, Ng AWY, Sze WK, Chan WL, Lee VHF, Lam WWT. Trajectories of sleep disturbance in cancer survivors during the first 2 years post-treatment. *Sleep*. 2023 Aug 14;46(8):zsad052. doi: 10.1093/sleep/zsad052. PMID: 36861253.

Mo Y, Leung LL, Mak CSL, Wang X, Chan WS, Hui LMN, Tang HWM, Siu MKY, Sharma R, Xu D, Tsui SKW, Ngan HYS, Yung MMH, Chan KKL, Chan DW. Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis. *Mol Cancer*. 2023 Jan 9;22(1):4. doi: 10.1186/s12943-022-01703-9. PMID: 36624516; PMCID: PMC9827705.

Luckett R, Feldman S, Woo YL, Moscicki AB, Giuliano AR, de Sanjosé S, Kaufmann AM, Leung SOA, Garcia F, Chan K, Bhatla N, Stanley M, Brotherton J, Palefsky J, Garland S; International Papillomavirus Society (IPVS) Policy Committee. COVID-19 as a catalyst for reimagining cervical cancer prevention. *Elife*. 2023 Apr 18;12:e86266. doi: 10.7554/eLife.86266. PMID: 37070731; PMCID: PMC10171861.

Luk HM, Ngu SF, Lau LSK, Tse KY, Chu MMY, Kwok ST, Ngan HYS, Chan KKL. Patient-Initiated Follow-Up in Ovarian Cancer. *Curr Oncol*. 2023 Mar 26;30(4):3627-3636. doi: 10.3390/curroncol30040276. PMID: 37185389; PMCID: PMC10136438.

Ng DWL, Fielding R, Tsang C, Ng C, Chan J, Or A, Kong IWM, Tang JWC, Li WWY, Chang ATY, Foo CC, Kwong A, Ng SS, Suen D, Chan M, Chun OK, Chan KKL, Butow PN, Lam WWT. Study protocol of ConquerFear-HK: a randomised controlled trial of a metacognition-based, manualised intervention for fear of cancer recurrence among Chinese cancer survivors. *BMJ Open*. 2023 Jan 20;13(1):e065075. doi: 10.1136/bmjopen-2022-065075. PMID: 36669845; PMCID: PMC9872480.

